X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with J.B.Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs J.B.CHEMICALS - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA J.B.CHEMICALS GSK PHARMA/
J.B.CHEMICALS
 
P/E (TTM) x 63.6 14.7 432.5% View Chart
P/BV x 10.2 2.3 439.3% View Chart
Dividend Yield % 1.2 0.2 743.4%  

Financials

 GSK PHARMA   J.B.CHEMICALS
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
J.B.CHEMICALS
Mar-16
GSK PHARMA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs3,838318 1,206.5%   
Low Rs2,637200 1,321.8%   
Sales per share (Unadj.) Rs354.2148.0 239.4%  
Earnings per share (Unadj.) Rs39.819.1 208.4%  
Cash flow per share (Unadj.) Rs42.923.9 179.0%  
Dividends per share (Unadj.) Rs30.000.50 6,000.0%  
Dividend yield (eoy) %0.90.2 479.6%  
Book value per share (Unadj.) Rs236.9128.9 183.7%  
Shares outstanding (eoy) m84.7084.82 99.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.11.7 522.6%   
Avg P/E ratio x81.413.6 600.4%  
P/CF ratio (eoy) x75.510.8 698.8%  
Price / Book Value ratio x13.72.0 680.8%  
Dividend payout %75.42.6 2,879.6%   
Avg Mkt Cap Rs m274,21621,951 1,249.2%   
No. of employees `0004.72.7 171.8%   
Total wages/salary Rs m4,8301,841 262.3%   
Avg. sales/employee Rs Th6,387.04,590.9 139.1%   
Avg. wages/employee Rs Th1,028.3673.4 152.7%   
Avg. net profit/employee Rs Th717.1592.1 121.1%   
INCOME DATA
Net Sales Rs m30,00012,551 239.0%  
Other income Rs m728542 134.5%   
Total revenues Rs m30,72813,093 234.7%   
Gross profit Rs m4,1902,055 203.9%  
Depreciation Rs m263412 63.8%   
Interest Rs m096 0.0%   
Profit before tax Rs m4,6552,088 222.9%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744469 371.8%   
Profit after tax Rs m3,3681,619 208.1%  
Gross profit margin %14.016.4 85.3%  
Effective tax rate %37.522.5 166.8%   
Net profit margin %11.212.9 87.1%  
BALANCE SHEET DATA
Current assets Rs m16,7427,778 215.3%   
Current liabilities Rs m7,2024,358 165.3%   
Net working cap to sales %31.827.2 116.7%  
Current ratio x2.31.8 130.3%  
Inventory Days Days5255 94.8%  
Debtors Days Days2180 26.0%  
Net fixed assets Rs m8,6355,713 151.2%   
Share capital Rs m847170 499.4%   
"Free" reserves Rs m19,22210,547 182.3%   
Net worth Rs m20,06910,937 183.5%   
Long term debt Rs m100-   
Total assets Rs m30,03815,574 192.9%  
Interest coverage xNM22.8-  
Debt to equity ratio x00-  
Sales to assets ratio x1.00.8 123.9%   
Return on assets %11.211.0 101.9%  
Return on equity %16.814.8 113.4%  
Return on capital %25.520.0 127.5%  
Exports to sales %048.7 0.0%   
Imports to sales %07.1 0.0%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs mNA889 0.0%   
Fx inflow Rs m5286,169 8.6%   
Fx outflow Rs m7,1931,285 559.7%   
Net fx Rs m-6,6654,884 -136.5%   
CASH FLOW
From Operations Rs m2,3601,397 169.0%  
From Investments Rs m3,008-320 -939.1%  
From Financial Activity Rs m-5,108-1,196 427.1%  
Net Cashflow Rs m260-102 -254.4%  

Share Holding

Indian Promoters % 0.0 55.4 -  
Foreign collaborators % 50.7 0.3 16,900.0%  
Indian inst/Mut Fund % 10.2 3.4 300.9%  
FIIs % 23.8 3.9 610.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 37.0 41.6%  
Shareholders   102,036 30,437 335.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS